Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.
2.

Suicidal and parasuicidal behavior in borderline personality disorder.

Gardner DL, Cowdry RW.

Psychiatr Clin North Am. 1985 Jun;8(2):389-403. Review.

PMID:
3895199
3.

Development of melancholia during carbamazepine treatment in borderline personality disorder.

Gardner DL, Cowdry RW.

J Clin Psychopharmacol. 1986 Aug;6(4):236-9.

PMID:
3525615
4.

Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder.

Gardner DL, Cowdry RW.

Am J Psychiatry. 1986 Apr;143(4):519-22.

PMID:
3513634
5.

Alprazolam-induced dyscontrol in borderline personality disorder.

Gardner DL, Cowdry RW.

Am J Psychiatry. 1985 Jan;142(1):98-100.

PMID:
2857071
6.

Psychopharmacology of borderline personality disorder: a review.

Cowdry RW.

J Clin Psychiatry. 1987 Aug;48 Suppl:15-25. Review.

PMID:
2886493
7.

The interaction of psychopharmacology and psychoanalysis in the borderline patient.

Snyder S.

Psychiatr Q. 1980 Winter;52(4):240-50. Review. No abstract available.

PMID:
6113616
8.

Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo.

Soloff PH, George A, Nathan RS, Schulz PM, Ulrich RF, Perel JM.

Arch Gen Psychiatry. 1986 Jul;43(7):691-7.

PMID:
3521532
9.

Pharmacotherapy for personality disorders.

Hori A.

Psychiatry Clin Neurosci. 1998 Feb;52(1):13-9. Review.

10.

A trial of carbamazepine in borderline personality disorder.

de la Fuente JM, Lotstra F.

Eur Neuropsychopharmacol. 1994 Dec;4(4):479-86.

PMID:
7894258
11.

An open trial of valproate in borderline personality disorder.

Stein DJ, Simeon D, Frenkel M, Islam MN, Hollander E.

J Clin Psychiatry. 1995 Nov;56(11):506-10.

PMID:
7592502
12.

A dramatic behavioral response to thyrotropin-releasing hormone following low-dose neuroleptics.

Garbutt JC, Loosen PT.

Psychoneuroendocrinology. 1984;9(3):311-4.

PMID:
6436858
13.

Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression.

Rickels K, Chung HR, Csanalosi IB, Hurowitz AM, London J, Wiseman K, Kaplan M, Amsterdam JD.

Arch Gen Psychiatry. 1987 Oct;44(10):862-6.

PMID:
3310952
14.

Efficacy of phenelzine and haloperidol in borderline personality disorder.

Soloff PH, Cornelius J, George A, Nathan S, Perel JM, Ulrich RF.

Arch Gen Psychiatry. 1993 May;50(5):377-85.

PMID:
8489326
15.

Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo.

Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, Hamer RM, Friedel RO.

Arch Gen Psychiatry. 1986 Jul;43(7):680-6.

PMID:
3521531
16.

Pharmacotherapy for patients with borderline personality disorder.

Gunderson JG.

Arch Gen Psychiatry. 1986 Jul;43(7):698-700. No abstract available.

PMID:
2872871
17.

A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder.

Hollander E, Allen A, Lopez RP, Bienstock CA, Grossman R, Siever LJ, Merkatz L, Stein DJ.

J Clin Psychiatry. 2001 Mar;62(3):199-203.

PMID:
11305707
18.

Sedative or antimanic effects of carbamazepine and treatment of behavioral dyscontrol.

Greenberg WM.

Am J Psychiatry. 1986 Nov;143(11):1486-7. No abstract available.

PMID:
3535545
19.
20.

Pharmacotherapy of the borderline patient: a critical review and clinical guidelines.

Kutcher SP, Blackwood DH.

Can J Psychiatry. 1989 May;34(4):347-53. Review.

PMID:
2567621

Supplemental Content

Support Center